When analyzing overall survival in a post-hoc manner sponsors need to carefully consider the types of analyses to present and have a thorough understanding of both the regulatory precedent and market landscape which their product will enter.
If you were born during the Spanish flu of 1918, you had a 2-3x higher risk of Parkinson’s. If COVID-19 caused the same viral damage, what does that mean for all of us? In this webinar, study author Pete Schmidt, PhD (Rho) and Mark Stacy,
Overall survival (OS) is both an important efficacy & safety endpoint for oncology trials. Often when study results are submitted for regulatory consideration, OS results are often “immature”/still in their early stages which makes them difficult to evaluate. Understanding how to place these results into a proper benefit-risk framework for consideration is therefore important when assessing a potential treatment’s viability.
Rho has once again been chosen as a winner of Triangle Business Journal’s 2023 Best Places to Work Awards. This is the 11th year Rho has been recognized for the Triangle Business Journal’s award “a prestigious award that honors companies for creating policies and a work environment that employees value.”
One of the most rewarding aspects of this recognition is that it is driven by employee surveys, which are then tabulated and ranked by Quantum Workplace. Rho is honored and proud to receive high marks in areas such as team effectiveness, trust with co-workers, manager effectiveness and work engagements from our employees.
Rho received Clinical Leader and Life Science Leader’s 2023 CRO Leadership award, marking a long history as an award recipient. Forty-six CROs were evaluated on more that 20 different performance metrics. Respondents evaluated companies with which they have worked on an outsourced project within the past 18 months. This level of qualification ensures that survey responses are based on actual involvement with CROs and clear experiential data.
Rho was recognized for Exceeding Customer Expectations in Compatibility and Quality and received 4 Individual Attribute Awards in Data Quality, Technology for Real Time Access to Data, Therapeutic Expertise and Operational Excellence.
Biometrics services (data management, biostatistics, data standards, and statistical programming) can be outsourced together as a unit or individually with different CRO partners. While splitting services up is perfectly acceptable, there are potential benefits that could be realized by having one contract research organization (CRO) support both the data management and biostatistical/programming components for your clinical trial project or program.
Nine out of 10 clinical trials for new drugs fail; Oncology drugs have a 3.4 percent probability of succeeding. Still, cancer drugs can and are being commercialized. From 2003 to 2020, 124 oncology therapies were approved by FDA. What makes this possible? Knowing the key factors to consider at each juncture
